Keros Therapeutics Files 8-K

Ticker: KROS · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1664710

Keros Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKeros Therapeutics, Inc. (KROS)
Form Type8-K
Filed DateMar 6, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-K, regulatory

Related Tickers: KROS

TL;DR

Keros filed a standard 8-K, no new news.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on March 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form type.

Why It Matters

This filing indicates Keros Therapeutics is meeting its regulatory reporting obligations with the SEC. It does not disclose new material information that would immediately impact the company's stock.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information or events that would inherently increase risk.

Key Players & Entities

  • Keros Therapeutics, Inc. (company) — Registrant
  • 0001664710-24-000031 (filing_id) — Accession Number
  • March 6, 2024 (date) — Filing Date
  • Lexington, Massachusetts (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing by Keros Therapeutics?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the Item Information section.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on March 6, 2024.

What is Keros Therapeutics' state of incorporation?

Keros Therapeutics, Inc. is incorporated in Delaware.

What is the address of Keros Therapeutics' principal executive offices?

The principal executive offices of Keros Therapeutics are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

Does this 8-K filing disclose any new financial results or material events?

Based on the provided text, this 8-K filing appears to be a routine report and does not explicitly disclose new financial results or specific material events beyond the standard reporting categories.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-06 08:01:41

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 6, 2024, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. Such information and the accompanying Exhibit 99.1 are not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation dated March 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: March 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.